quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·50d
PRRelease
Entera Bio Ltd. logo

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

ENTX· Entera Bio Ltd.
Health Care
Original source

Companies

  • ENTX
    Entera Bio Ltd.
    Health Care

Related

  • PR3d
    BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
  • PR9d
    Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
  • PR17d
    Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
  • SEC20d
    Entera Bio Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
  • PR21d
    Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
  • SEC27d
    SEC Form 10-K filed by Entera Bio Ltd.
  • SEC27d
    Entera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR27d
    Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022